Raymond J. March
| Thursday November 15, 2018 at 10:00 AM PST
Right-to-try will never reach its potential without deregulation.
John R. Graham
| Wednesday February 24, 2016 at 9:30 AM PST
A recent Kaiser Family Foundation Tracking Poll brings dire news for innovative drug companies: 83 percent of the survey’s respondents favor a policy “allowing the federal government to negotiate drug prices for Medicare beneficiaries.” That includes 93 percent of Democrats and 74 percent of Republicans. There is no point discussing the rationality of this...Read More »